Tubal Ectopic Pregnancy: Effect of ß-hCG Change in Treatment


  • Mehmet Özer Health Sciences University Tepecik Education and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey
  • Yasemin Alan Department of Obstetrics and Gynecology, İzmir Metropolitan Municipality Eşrefpaşa Hospital, İzmir, Turkey
  • Aşkın Doğan Health Sciences University Tepecik Education and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey
  • Murat Alan Health Sciences University Tepecik Education and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey




Tubal ectopic pregnancies, β-hCG, methotrexate.


Objective: To evaluate the effect of β-hCG of treating prediction in tubal ectopic pregnancies (TEP).

Materials and Methods: 758 patients receiving only one dose of methotrexate (mtx) treatment protocol for CAP were included in the study between January 2009 and December 2017. Patients' age, gravity, parity, ultrasonography findings, β-hCG values, and factors that may affect treatming process were recorded.

Results: It was determined that medical treatment success was predicted with 77%, 81% sensitivity and 61% and 68% specificity when the initial β-hCG value was 1435 mIU / mL and the β-hCG level on the 4th day was 1539 mIU / mL cut off value. In our study, when β-hCG values decreased by 7% between 0-4 days were taken as cut off value, medical treatment with 84% sensitivity and 77% specificity was shown to be successful. The mean β-hCG levels on the 4th and 7th days were significantly lower in the medical treatment group than in the unsuccessful group.

Conclusion: We found that patients with lower β-hCG values at baseline and day 4 had higher chances of success, and when cut off values were taken as 1435 mIU / mL and 1539 mIU / mL, success rate was significantly decreased. According to β-hCG level on day 0, day 4, and β-hCG change level between 0-4 days, we think ectopic pregnancy approach will decrease the unnecessary hospital stay.


Lozeau AM, Potter B. Diagnosis and management of ectopic pregnancy. Am Fam Physician 2005; 72(9): 1707-1714.

Chang J, Elem-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance: United States, 1991–1999. 1. MMWR Surveill Summ 2003; 52(2): 1-8.

Goldner TE, Lawson HW, Xia Z, Atrash HK. Surveillance for ectopic pregnancy-United States,1970-1989. MMWR CDC Surveill Summ 1993; 42(6): 73-85.

Saraiya M, Berg CJ, Shulman H, Green CA, Atrash HK. Estimates of the annual number of clinically recognized pregnancies in the United States, 1981-1991. Am J Epidemiol 1999; 149(11): 1025-1029. https://doi.org/10.1093/oxfordjournals.aje.a009747

Halbert SA, Becker DR, Szal SE. Ovum transport in the rat oviductal ampulla in the absence of muscle contractility. Biol Reprod 1989; 40(6): 1131-6. https://doi.org/10.1095/biolreprod40.6.1131

Lyons RA, Saridogan E, Djahanbakhch O. The reproductive significance of human fallopian tube cilia. Hum Reprod Update 2006; 12(4): 363-72. https://doi.org/10.1093/humupd/dml012

Della-Giustina D, Denny M. Ectopic pregnancy. Emerg Med Clin North Am 2003; 21(3): 565-84. https://doi.org/10.1016/S0733-8627(03)00036-1

Dialani V, Levine D. Ectopic pregnancy: a review. Ultrasound Q 2004; 20(3): 105-17. https://doi.org/10.1097/00013644-200409000-00005

Pellerito JS, Taylor KJ, Quedens-Case C, et al. Ectopic pregnancy: evaluation with endovaginal color flow imaging. Radiology 1992; 183(2): 407-11. https://doi.org/10.1148/radiology.183.2.1561341

Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol 1993; 168(6 Pt 1): 1759-62; discussion 1762-5. https://doi.org/10.1016/0002-9378(93)90687-E

Kirk E, Condous G, Bourne T. The non-surgical management of ectopic pregnancy. Ultrasound Obstet Gynecol 2006; 27(1): 91-100. https://doi.org/10.1002/uog.2602

Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol 2003; 101(4): 778-84. https://doi.org/10.1097/00006250-200304000-00028

Tosun M, Işık Y, Avcı B. The role of early determination of βhuman chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy. Ginekol Pol 2016; 87(7): 484-7. https://doi.org/10.5603/GP.2016.0030

Lecuru F, Robin F. Direct cost of single dose methotrexate for unruptured ectopic pregnancy. Prospective comparison with laparoscopy. Eur J Obstet Gynecol Reprod Biol 2000; 88(1): 1-6. https://doi.org/10.1016/S0301-2115(99)00125-6

Michalas S, Minaretzis D, Tsionou C, Maos G, Kioses E, Aravantinos D. Pelvic surgery, reproductive factors and risk of ectopic pregnancy: a case controlled study. Int J Gynaecol Obstet 1992; 38(2): 101-5. https://doi.org/10.1016/0020-7292(92)90044-J

Gracia CR, Barnhart KT 2001. Diagnosing ectopic pregnancy: decision analysis comparing six strategies. Obstet Gynecol 2001; 97(3): 464-70. https://doi.org/10.1097/00006250-200103000-00028

Sorian D, Hugol D, Quang NT, Darai E. Serum concentrations of interleukin-2R (IL-2R), IL-6, IL-8, and tumor necrosis factor alpha in patients with ectopic pregnancy. Fertil Steril 2003; 79(4): 975-80. https://doi.org/10.1016/S0015-0282(02)04853-7

Tawfiq A, Agameya AF, Claman P. Predictors of treatment failure for ectopic pregnancy treated with single-dose methotrexate. Fertil Steril 2000; 74(5): 877-80. https://doi.org/10.1016/S0015-0282(00)01547-8

Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999; 341(26): 1974-8. https://doi.org/10.1056/NEJM199912233412604

Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87(3): 481-4. https://doi.org/10.1016/j.fertnstert.2006.10.007

Nowak-Markwitz E, Michalak M, Olejnik M, Spaczynski M. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril 2009; 92(4): 1203-7. https://doi.org/10.1016/j.fertnstert.2008.07.1775

Natale A,Busacca M, Candiani M, Gruft L, Izzo S, Felicetta I, Vignali M. Human chorionic gonadotropin patterns after a single dose of methotrexate for ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 100(2): 227-30. https://doi.org/10.1016/S0301-2115(01)00480-8

Agostini A, Blanc K,Ronda I, Romain F, Capelle M, Blanc B. Prognostic value of human chorionic gonadotropin changes after methotrexate injection for ectopic pregnancy. Fertil Steril 2007; 88(2): 504-6. https://doi.org/10.1016/j.fertnstert.2006.11.138

Celik E, Türkçüoğlu I, Karaer A, Kırıcı P, Eraslan S. Assessment of early decline in the percentage of β-hCG values between days 0 and 4 after methotrexate therapy in ectopic pregnancy for the prediction of treatment success. J Turk Ger Gynecol Assoc 2013; 14(3): 125-9. https://doi.org/10.5152/jtgga.2013.50133

Üstünyurt E, Duran M, Coskun E, Üstunyurt ÖB, Şimşek H. Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy. Arch Gynecol Obstet 2013; 288(5): 1149-52. https://doi.org/10.1007/s00404-013-2879-8

Cohen A, Bibi G, Almog B, Tsafrir Z, Levin I. Second-dose methotrexate in ectopic pregnancies: the role of beta human chorionic gonadotropin. Fertil Steril 2014; 102(6): 1646-9. https://doi.org/10.1016/j.fertnstert.2014.08.019

Atkinson M, Gupta S, Mcgee T. βhCG monitoring after single-dose methotrexate treatment of tubal ectopic pregnancy: is the Day 4 βhCG necessary? A retrospective cohort study. Aust N Z J Obstet Gynaecol 2014; 54(5): 475-9. https://doi.org/10.1111/ajo.12257